Antares Pharma (ATRS) 10-Q 6 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 31, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	ATRS
Security Exchange Name	NASDAQ
Entity Registrant Name	ANTARES PHARMA, INC.
Entity Central Index Key	0001016169
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, par value $0.01 per share
Entity Common Stock, Shares Outstanding		166,093,874
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity File Number	1-32302
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1350192
Entity Address, Address Line One	100 Princeton South
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Ewing
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08628
City Area Code	609
Local Phone Number	359-3020
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 43,558	$ 23,201
Short-term investments	7,992	22,520
Accounts receivable	34,293	35,074
Inventories	19,605	16,000
Contract assets	7,013	8,235
Prepaid expenses and other current assets	3,302	3,416
Total current assets	115,763	108,446
Equipment, molds, furniture and fixtures, net	19,452	15,961
Operating lease right-of-use assets	4,860	5,463
Other assets	3,049	2,881
Total Assets	143,124	132,751
Current Liabilities:
Accounts payable	18,071	12,905
Accrued expenses and other liabilities	18,332	16,523
Operating lease liabilities, current portion	1,230	1,249
Deferred revenue	2,341	1,738
Total current liabilities	39,974	32,415
Long-term debt	40,647	40,395
Operating lease liabilities, long-term	4,980	5,441
Other long-term liabilities	194
Total liabilities	85,795	78,251
Stockholders’ Equity:
Preferred Stock: $0.01 par; 3,000 shares authorized, none outstanding
Common Stock: $0.01 par; 300,000 shares authorized; 166,085 and 165,221 issued and outstanding at June 30, 2020 and December 31, 2019, respectively	1,661	1,652
Additional paid-in capital	335,372	332,377
Accumulated deficit	(279,008)	(278,827)
Accumulated other comprehensive loss	(696)	(702)
Total Stockholders' Equity	57,329	54,500
Total Liabilities and Stockholders’ Equity	$ 143,124	$ 132,751

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	166,085,000	165,221,000
Common Stock, shares outstanding	166,085,000	165,221,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Total revenue	$ 32,384	$ 28,433	$ 65,463	$ 51,719
Cost of revenue:
Total cost of revenue	12,477	12,441	27,524	23,387
Gross profit	19,907	15,992	37,939	28,332
Operating expenses:
Research and development	2,417	2,494	5,398	4,881
Selling, general and administrative	14,448	15,087	30,870	30,022
Total operating expenses	16,865	17,581	36,268	34,903
Operating income (loss)	3,042	(1,589)	1,671	(6,571)
Interest expense	(967)	(712)	(2,028)	(1,373)
Other income	100	75	176	179
Net income (loss)	$ 2,175	$ (2,226)	$ (181)	$ (7,765)
Net income (loss) per common share, basic and diluted	$ 0.01	$ (0.01)	$ 0	$ (0.05)
Weighted average common shares outstanding:
Basic	165,703	162,734	165,566	161,596
Diluted	169,228	162,734	165,566	161,596
Product sales [Member]
Revenue:
Total revenue	$ 24,665	$ 20,620	$ 51,762	$ 38,920
Cost of revenue:
Total cost of revenue	10,927	10,713	24,941	21,281
Licensing and Development Revenue [Member]
Revenue:
Total revenue	2,687	2,239	4,442	3,154
Royalties [Member]
Revenue:
Total revenue	5,032	5,574	9,259	9,645
Cost of development revenue [Member]
Cost of revenue:
Total cost of revenue	$ 1,550	$ 1,728	$ 2,583	$ 2,106

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 2,175	$ (2,226)	$ (181)	$ (7,765)
Foreign currency translation adjustment	4	2	6	(1)
Comprehensive income (loss)	$ 2,179	$ (2,224)	$ (175)	$ (7,766)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Cumulative Effect of Change in Accounting Principle [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]Cumulative Effect of Change in Accounting Principle [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2018	$ 39,001		$ 1,597	$ 314,907	$ (276,800)		$ (703)
Balance, shares at Dec. 31, 2018			159,721,000
Issuance of common stock	7,780		$ 23	7,757
Issuance of common stock, shares			2,307,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(1,063)		$ 7	(1,070)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares			654,000
Exercise of options	484		$ 4	480
Exercise of options, shares			371,000
Share-based compensation	3,001			3,001
Net income (loss)	(7,765)				(7,765)
Other comprehensive income (loss)	(1)						(1)
Balance at Jun. 30, 2019	41,552	$ 116	$ 1,631	325,075	(284,449)	$ 116	(704)
Balance, shares at Jun. 30, 2019			163,053,000
Balance at Mar. 31, 2019	42,668		$ 1,625	323,972	(282,223)		(706)
Balance, shares at Mar. 31, 2019			162,528,000
Issuance of common stock	(5)			(5)
Common stock issued under equity compensation plan, net of shares withheld for taxes	(655)		$ 4	(659)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares			366,000
Exercise of options	134		$ 2	132
Exercise of options, shares			159,000
Share-based compensation	1,635			1,635
Net income (loss)	(2,226)				(2,226)
Other comprehensive income (loss)	2						2
Balance at Jun. 30, 2019	41,552	$ 116	$ 1,631	325,075	(284,449)	$ 116	(704)
Balance, shares at Jun. 30, 2019			163,053,000
Balance at Dec. 31, 2019	54,500		$ 1,652	332,377	(278,827)		(702)
Balance, shares at Dec. 31, 2019			165,221,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(1,350)		$ 7	(1,357)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares			669,000
Exercise of options	389		$ 2	387
Exercise of options, shares			195,000
Share-based compensation	3,965			3,965
Net income (loss)	(181)				(181)
Other comprehensive income (loss)	6						6
Balance at Jun. 30, 2020	57,329		$ 1,661	335,372	(279,008)		(696)
Balance, shares at Jun. 30, 2020			166,085,000
Balance at Mar. 31, 2020	53,798		$ 1,656	334,025	(281,183)		(700)
Balance, shares at Mar. 31, 2020			165,560,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(753)		$ 4	(757)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares			451,000
Exercise of options	118		$ 1	117
Exercise of options, shares			74,000
Share-based compensation	1,987			1,987
Net income (loss)	2,175				2,175
Other comprehensive income (loss)	4						4
Balance at Jun. 30, 2020	$ 57,329		$ 1,661	$ 335,372	$ (279,008)		$ (696)
Balance, shares at Jun. 30, 2020			166,085,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (181)	$ (7,765)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense	3,965	3,000
Depreciation and amortization	1,132	1,338
Other	519	154
Changes in operating assets and liabilities:
Accounts receivable	785	(5,654)
Inventories	(3,605)	(3,885)
Contract assets	1,222	1,657
Prepaid expenses and other assets	(106)	(506)
Accounts payable	3,680	507
Accrued expenses and other liabilities	1,247	443
Deferred revenue	603	(471)
Net cash provided by (used in) operating activities	9,261	(11,182)
Cash flows from investing activities:
Proceeds from sale of assets		2,500
Purchases of equipment, molds, furniture and fixtures	(2,444)	(1,104)
Proceeds from maturities of investment securities	14,500
Net cash provided by investing activities	12,056	1,396
Cash flows from financing activities:
Proceeds from issuance of long-term debt		15,000
Payment of debt issuance costs		(136)
Proceeds from issuance of common stock, net		7,781
Proceeds from exercise of stock options	389	484
Taxes paid related to net share settlement of equity awards	(1,350)	(1,063)
Net cash provided by (used in) financing activities	(961)	22,066
Effect of exchange rate changes on cash	1	(1)
Net increase in cash and cash equivalents	20,357	12,279
Cash and cash equivalents:
Beginning of period	23,201	27,892
End of period	43,558	40,171
Supplemental disclosure of cash flow information:
Cash paid for interest	1,810	1,201
Supplemental disclosure of non-cash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	$ 3,334	$ 106

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. Description of Business Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. We develop, manufacture and commercialize, for ourselves or with partners, novel therapeutic products using advanced drug delivery technology to enhance existing drug compounds and delivery methods. Our injection technology platforms include the VIBEX ® ® ® The Company directly markets and sells two proprietary products in the United States, XYOSTED ® ® ® ® Through our commercialization partner Teva, we sell Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults. In collaboration with AMAG, we developed a subcutaneous auto injector and are the exclusive supplier of devices and the final assembled and packaged commercial product of AMAG’s Makena ® Through a license, development and supply agreement with Teva, Antares developed and is the exclusive supplier of the device for Teva’s Epinephrine Injection USP, which is indicated for emergency treatment of severe allergic reactions in adults and certain pediatric patients. The Company is also developing two multi-dose pen injector products in collaboration with Teva, a combination drug device rescue pen in collaboration with Pfizer, a combination drug device product with Idorsia, and has other ongoing internal and partnered research and development programs.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission's Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying consolidated financial statements and notes thereto should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. Accounting Pronouncements Recently Adopted The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2018-15 Customers’ Accounting for Implementation Costs Incurred in Cloud Computing Arrangement that is a Service Contract, The Company adopted ASU No. 2018-18 Clarifying the Interaction Between Topic 808 and 606 revenue guidance, adds unit of account guidance to the collaborative arrangement guidance to align with the revenue standard, and clarifies presentation guidance for transactions with a collaborative arrangement participant that is not accounted for under the revenue standard. The Company ’s adoption of this standard did not have a material impact on its consolidated financial statements . Recent Accounting Pronouncements Not Yet Adopted In 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments However, in October 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective Dates . Investments From time to time, the Company invests in U.S. Treasury bills and government agency notes that are classified as held-to-maturity because of the Company’s intent and ability to hold the securities to maturity. Investments with maturities of one year or less are classified as short-term. The securities are carried at their amortized cost and the fair value is determined by quoted market prices. The Company’s short-term investments had a carrying value of $7,992 and $22,520 as of June 30, 2020 and December 31, 2019, respectively, which approximated fair value. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $499 and $464 at June 30, 2020 and December 31, 2019, respectively. Inventories consist of the following: June 30, December 31, 2020 2019 Inventories: Raw material $ 325 $ 325 Work in process 11,350 8,390 Finished goods 7,930 7,285 $ 19,605 $ 16,000 Equipment, Molds, Furniture, and Fixtures Equipment, molds, furniture, and fixtures are stated at cost, net of accumulated depreciation, and are depreciated using the straight-line method over their estimated useful lives ranging from three to ten years. As of June 30, 2020 and December 31, 2019, the Company’s equipment, molds, furniture and fixtures totaled $19,452 and $15,961, respectively, which is presented net of accumulated depreciation of $10,379 and $9,769 as of June 30, 2020 and December 31, 2019, respectively. Revenue Recognition The Company generates revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Revenue is recognized when or as the Company transfers control of the promised goods or services to its customers at the transaction price, which is the amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. At inception of each contract, the Company identifies the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company reassesses its reserves for variable consideration at each reporting date and makes adjustments, if necessary, The Company has elected to recognize the cost for freight and shipping activities as fulfilment cost. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenue. Proprietary Product Sales The Company sells its proprietary products XYOSTED ® ® The determination of certain of these reserves and sales allowances require management to make a number of judgements and estimates to reflect the Company’s best estimate of the transaction price and the amount of consideration to which it believes it is ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and expected utilization rates, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. Reserves for prompt payment discounts are recorded as a reduction in accounts receivable. Reserves for returns, rebates and chargebacks, distributor fees and customer co-pay support programs are included within current liabilities in the consolidated balance sheets. Partnered Product Sales The Company is party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which the Company produces and is the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as follows: The Company is the exclusive supplier of the Makena ® All other partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no price protection or right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, if any. For example, the Company sells Sumatriptan Injection USP to Teva at cost and is entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the end of the quarter in which the commercial sales are made. The Company recognizes revenue, including the estimated variable consideration it expects to receive for contract margin on future commercial sales, upon shipment of the goods to Teva. The estimated variable consideration is recognized at an amount the Company believes is not subject to significant reversal based on historical experience, and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed. Licensing and Development Revenue The Company has entered into several license, development and supply arrangements with pharmaceutical partners under which the Company grants a license to its device technology and know-how and provides research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, the Company identifies each of the promised goods and services within the contract and the distinct performance obligations at inception, and allocates consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus margin. If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, the Company recognizes revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and the Company has a present right to payment. The Company’s typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. The Company records a contract liability for cash received in advance of performance, which is presented within deferred revenue on the consolidated balance sheet and recognized as revenue when the associated performance obligations have been satisfied. The Company recognized $780 in licensing and development revenue in connection with contract liabilities that were outstanding as of December 31, 2019 and satisfied during the six months ended June 30, 2020. License fees and milestones received in exchange for the grant of a license to the Company’s functional intellectual property such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is not generally distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved. Royalties The Company earns royalties in connection with licenses granted under license and development arrangements with partners. Royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digit to low double digit and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners’ commercial sales occur. The royalties are generally reported and payable to the Company within 45 to 60 days of the end of the period in which the commercial sales are made. The Company bases its estimates of royalties earned on actual sales information from its partners when available or estimated prescription sales from external sources and estimated net selling price. If actual royalties received are different than amounts estimated, the Company would adjust the royalty revenue in the period in which the adjustment becomes known. Remaining Performance Obligations Remaining performance obligations represents the allocation of transaction price of firm orders and development contract deliverables for which work has not been completed or orders fulfilled, and excludes potential purchase orders under ordering-type supply contracts with indefinite delivery or quantity. As of June 30, 2020, the aggregate value of remaining performance obligations, excluding contracts with an original expected length of one year or less, was $24.4 million. The Company expects to recognize revenue on the remaining performance obligations over the next five years.

Share Based Compensation

Share Based Compensation	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Based Compensation	3 . Share-Based Compensation The Company has an Equity Compensation Plan (the “Plan”), which allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. The Company also has a long-term incentive program (“LTIP”), pursuant to which the Company’s senior executives have been awarded stock options, restricted stock units (“RSUs”) and performance stock units (“PSUs”). The following is a summary of stock option activity under the Plan as of and for the six months ended June 30, 2020: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at December 31, 2019 13,861 $ 2.41 Granted 3,075 2.73 Exercised 195 1.99 Cancelled/Forfeited 243 2.89 Outstanding at June 30, 2020 16,498 2.47 6.8 $ 6,089 Exercisable at June 30, 2020 11,462 $ 2.31 5.7 $ 5,997 The following is a summary of PSU and RSU award activity under the Plan as of and for the six months ended June 30, 2020: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2019 1,841 $ 3.00 1,401 $ 2.82 Granted 605 2.00 1,078 2.73 Incremental shares earned 77 — — — Vested/settled (388 ) 3.11 (772 ) 2.79 Forfeited/expired (395 ) 3.12 (45 ) 2.92 Outstanding at June 30, 2020 1,740 $ 2.61 1,662 $ 2.77 The PSUs granted to senior executives under the LTIP are expressed as a target number of shares in the table above and may be earned based upon the Company’s achievement of certain corporate development goals, net revenue goals and total shareholder return (“TSR”) relative to the Nasdaq Biotechnology Index over the performance period, which is generally a three-year The LTIP awards that vested during the six months ended June 30, 2020 and 2019 were net-share settled such that the Company withheld shares with a value equivalent to the employees’ tax obligations for applicable income and other employment taxes, and remitted cash to the appropriate taxing authorities. The Company withheld 419 and 362 shares during the six months ended June 30, 2020 and 2019, respectively, to satisfy tax obligations, which was determined based on the fair value of the shares on their vesting date equal to the Company’s closing stock price on such date. The Company paid $1,350 and $1,063 during the six months ended June 30, 2020 and 2019, respectively, to taxing authorities for the employees’ tax obligations, which is reflected as a cash outflow from financing activities within the consolidated statements of cash flows. Net-share settlements have the effect of share repurchases by the Company as they reduce the number of shares that would have otherwise been issued as a result of the vesting. In connection with Plan awards, the Company recognized share-based compensation expense for the three and six months ended June 30, 2020 and 2019 as follows: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Stock options $ 875 $ 758 $ 1,756 $ 1,666 Restricted stock units 525 371 1,082 702 Performance stock units 587 505 1,127 632 Total share-based compensation expense $ 1,987 $ 1,634 $ 3,965 $ 3,000

Revenues, Significant Customers

Revenues, Significant Customers and Concentrations of Risk	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenues, Significant Customers and Concentrations of Risk	4 . Revenues, Significant Customers and Concentrations of Risk The following table presents the Company’s revenue on a disaggregated basis by types of goods and services and major product lines: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Proprietary product sales $ 14,846 $ 8,984 $ 27,412 $ 13,755 Partnered product sales 9,819 11,636 24,350 25,165 Total product revenue 24,665 20,620 51,762 38,920 Licensing and development revenue 2,687 2,239 4,442 3,154 Royalties 5,032 5,574 9,259 9,645 Total revenue $ 32,384 $ 28,433 $ 65,463 $ 51,719 Revenues disaggregated by customer location are as follows: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 United States of America $ 31,798 $ 27,542 $ 64,268 $ 48,727 Europe 586 788 1,195 2,878 Other — 103 — 114 $ 32,384 $ 28,433 $ 65,463 $ 51,719 The following table identifies customers from which the Company derived 10% or more of its total revenue in any of the periods presented: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Teva 40% 42% 41% 44% AMAG 8% 19% 12% 19% AmerisourceBergen Corporation 13% 11% 13% <10% McKesson Corporation 11% <10% 11% <10% Cardinal Health 13% <10% 11% <10%

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	5 . Earnings Per Share Basic earnings or loss per common share is computed by dividing the net income or loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per common share is computed in a similar manner, except that the weighted average number of shares outstanding is increased to reflect the potential dilution from the exercise or conversion of securities into common stock. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if such instruments are dilutive in nature with respect to earnings per share. The dilutive effect of stock options and other equity-based awards included in the diluted weighted average common shares outstanding used in the computation of diluted earnings per share for the three months ended June 30, 2020 was 3,525 shares. For the six months ended June 30, 2020 and the three and six months ended June 30, 2019, the potentially dilutive stock options and other share-based awards excluded from the calculation of loss per share because the effect was anti-dilutive for the respective periods totaled 19,900 and 19,264 at June 30, 2020 and 2019, respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	6 . Commitments and Contingencies Pending Litigation From time to time, the Company may be involved in various legal matters generally incidental to its business. Although the results of litigation and claims cannot be predicted with certainty, after discussion with legal counsel, management is not aware of any matters for which the likelihood of a loss is probable and reasonably estimable and which could have a material impact on its consolidated financial condition, liquidity, or results of operations. On October 23, 2017, Randy Smith filed a complaint in the District of New Jersey, captioned Randy Smith, Individually and on Behalf of All Others Similarly Situated v. Antares Pharma, Inc., Robert F. Apple and Fred M. Powell Smith ® ® Smith On January 12, 2018, a stockholder of the Company filed a derivative civil action, captioned Chiru Mackert, derivatively on behalf of Antares Pharma, Inc., v. Robert F. Apple, et al. Vikram Rao, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. Smith Smith On January 17, 2018, a stockholder of the Company filed a derivative civil action, captioned Robert Clark, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. (“ Clark ”) (Case No. 3:18-cv-00703-MAS-DEA), against Robert F. Apple, Thomas J. Garrity, Jacques Gonella, Leonard S. Jacob, Marvin Samson, Anton G. Gueth and Robert P. Roche, Jr. as defendants, and Company as a nominal defendant. The action was filed in the U.S. District Court for the District of New Jersey and asserts claims for breach of fiduciary duties, unjust enrichment, abuse of control, waste of corporate assets, and a violation of Section 14(a) of the Securities Exchange Act of 1934. This complaint relates to the same facts underlying the Smith securities class action and the other derivative actions. The plaintiff in Clark seeks damages, corporate governance and internal procedure reforms and improvements, reasonable attorneys’ fees, accountants’ and experts’ fees, costs, and expenses. The parties have filed a stipulation staying the action pending the court’s decision on defendants’ motion to dismiss the Smith action.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Accounting Pronouncements Recently Adopted The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2018-15 Customers’ Accounting for Implementation Costs Incurred in Cloud Computing Arrangement that is a Service Contract, The Company adopted ASU No. 2018-18 Clarifying the Interaction Between Topic 808 and 606 revenue guidance, adds unit of account guidance to the collaborative arrangement guidance to align with the revenue standard, and clarifies presentation guidance for transactions with a collaborative arrangement participant that is not accounted for under the revenue standard. The Company ’s adoption of this standard did not have a material impact on its consolidated financial statements . Recent Accounting Pronouncements Not Yet Adopted In 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments However, in October 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective Dates .
Investments	Investments From time to time, the Company invests in U.S. Treasury bills and government agency notes that are classified as held-to-maturity because of the Company’s intent and ability to hold the securities to maturity. Investments with maturities of one year or less are classified as short-term. The securities are carried at their amortized cost and the fair value is determined by quoted market prices. The Company’s short-term investments had a carrying value of $7,992 and $22,520 as of June 30, 2020 and December 31, 2019, respectively, which approximated fair value.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $499 and $464 at June 30, 2020 and December 31, 2019, respectively. Inventories consist of the following: June 30, December 31, 2020 2019 Inventories: Raw material $ 325 $ 325 Work in process 11,350 8,390 Finished goods 7,930 7,285 $ 19,605 $ 16,000
Equipment, Molds, Furniture, and Fixtures	Equipment, Molds, Furniture, and Fixtures
Revenue Recognition	Revenue Recognition The Company generates revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Revenue is recognized when or as the Company transfers control of the promised goods or services to its customers at the transaction price, which is the amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. At inception of each contract, the Company identifies the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company reassesses its reserves for variable consideration at each reporting date and makes adjustments, if necessary, The Company has elected to recognize the cost for freight and shipping activities as fulfilment cost. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenue. Proprietary Product Sales The Company sells its proprietary products XYOSTED ® ® The determination of certain of these reserves and sales allowances require management to make a number of judgements and estimates to reflect the Company’s best estimate of the transaction price and the amount of consideration to which it believes it is ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and expected utilization rates, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. Reserves for prompt payment discounts are recorded as a reduction in accounts receivable. Reserves for returns, rebates and chargebacks, distributor fees and customer co-pay support programs are included within current liabilities in the consolidated balance sheets. Partnered Product Sales The Company is party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which the Company produces and is the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as follows: The Company is the exclusive supplier of the Makena ® All other partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no price protection or right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, if any. For example, the Company sells Sumatriptan Injection USP to Teva at cost and is entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the end of the quarter in which the commercial sales are made. The Company recognizes revenue, including the estimated variable consideration it expects to receive for contract margin on future commercial sales, upon shipment of the goods to Teva. The estimated variable consideration is recognized at an amount the Company believes is not subject to significant reversal based on historical experience, and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed. Licensing and Development Revenue The Company has entered into several license, development and supply arrangements with pharmaceutical partners under which the Company grants a license to its device technology and know-how and provides research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, the Company identifies each of the promised goods and services within the contract and the distinct performance obligations at inception, and allocates consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus margin. If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, the Company recognizes revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and the Company has a present right to payment. The Company’s typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. The Company records a contract liability for cash received in advance of performance, which is presented within deferred revenue on the consolidated balance sheet and recognized as revenue when the associated performance obligations have been satisfied. The Company recognized $780 in licensing and development revenue in connection with contract liabilities that were outstanding as of December 31, 2019 and satisfied during the six months ended June 30, 2020. License fees and milestones received in exchange for the grant of a license to the Company’s functional intellectual property such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is not generally distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved. Royalties The Company earns royalties in connection with licenses granted under license and development arrangements with partners. Royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digit to low double digit and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners’ commercial sales occur. The royalties are generally reported and payable to the Company within 45 to 60 days of the end of the period in which the commercial sales are made. The Company bases its estimates of royalties earned on actual sales information from its partners when available or estimated prescription sales from external sources and estimated net selling price. If actual royalties received are different than amounts estimated, the Company would adjust the royalty revenue in the period in which the adjustment becomes known. Remaining Performance Obligations Remaining performance obligations represents the allocation of transaction price of firm orders and development contract deliverables for which work has not been completed or orders fulfilled, and excludes potential purchase orders under ordering-type supply contracts with indefinite delivery or quantity. As of June 30, 2020, the aggregate value of remaining performance obligations, excluding contracts with an original expected length of one year or less, was $24.4 million. The Company expects to recognize revenue on the remaining performance obligations over the next five years.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Inventories	Inventories consist of the following: June 30, December 31, 2020 2019 Inventories: Raw material $ 325 $ 325 Work in process 11,350 8,390 Finished goods 7,930 7,285 $ 19,605 $ 16,000

Share Based Compensation (Table

Share Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	The following is a summary of stock option activity under the Plan as of and for the six months ended June 30, 2020: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at December 31, 2019 13,861 $ 2.41 Granted 3,075 2.73 Exercised 195 1.99 Cancelled/Forfeited 243 2.89 Outstanding at June 30, 2020 16,498 2.47 6.8 $ 6,089 Exercisable at June 30, 2020 11,462 $ 2.31 5.7 $ 5,997
Summary of PSU and RSU Award Activity Under Plan	The following is a summary of PSU and RSU award activity under the Plan as of and for the six months ended June 30, 2020: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2019 1,841 $ 3.00 1,401 $ 2.82 Granted 605 2.00 1,078 2.73 Incremental shares earned 77 — — — Vested/settled (388 ) 3.11 (772 ) 2.79 Forfeited/expired (395 ) 3.12 (45 ) 2.92 Outstanding at June 30, 2020 1,740 $ 2.61 1,662 $ 2.77
Summary of Share Based Compensation Allocation Expense	In connection with Plan awards, the Company recognized share-based compensation expense for the three and six months ended June 30, 2020 and 2019 as follows: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Stock options $ 875 $ 758 $ 1,756 $ 1,666 Restricted stock units 525 371 1,082 702 Performance stock units 587 505 1,127 632 Total share-based compensation expense $ 1,987 $ 1,634 $ 3,965 $ 3,000

Revenues, Significant Custome_2

Revenues, Significant Customers and Concentrations of Risk (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Summary of Revenues Disaggregated by Types of Goods and Services and Major Product and Customer Location	The following table presents the Company’s revenue on a disaggregated basis by types of goods and services and major product lines: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Proprietary product sales $ 14,846 $ 8,984 $ 27,412 $ 13,755 Partnered product sales 9,819 11,636 24,350 25,165 Total product revenue 24,665 20,620 51,762 38,920 Licensing and development revenue 2,687 2,239 4,442 3,154 Royalties 5,032 5,574 9,259 9,645 Total revenue $ 32,384 $ 28,433 $ 65,463 $ 51,719 Revenues disaggregated by customer location are as follows: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 United States of America $ 31,798 $ 27,542 $ 64,268 $ 48,727 Europe 586 788 1,195 2,878 Other — 103 — 114 $ 32,384 $ 28,433 $ 65,463 $ 51,719
Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue	The following table identifies customers from which the Company derived 10% or more of its total revenue in any of the periods presented: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Teva 40% 42% 41% 44% AMAG 8% 19% 12% 19% AmerisourceBergen Corporation 13% 11% 13% <10% McKesson Corporation 11% <10% 11% <10% Cardinal Health 13% <10% 11% <10%

Description of Business - Addit

Description of Business - Additional Information (Detail)	Jun. 30, 2020ProprietaryProduct
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of proprietary products directly marketed and sold	2

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Carrying value of short-term investments	$ 7,992	$ 22,520
Inventory reserve	499	464
Equipment, molds, furniture and fixtures, net	19,452	15,961
Accumulated depreciation	10,379	$ 9,769
Remaining performance obligations	$ 24,400
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation	The Company expects to recognize revenue on the remaining performance obligations over the next five years.
Licensing and Development Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized	$ 780
Teva [Member]
Summary Of Significant Accounting Policies [Line Items]
Future net profits from commercial sales percent	50.00%
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	3 years
Royalty payment period	45 days
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	10 years
Royalty payment period	60 days

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw material	$ 325	$ 325
Work in process	11,350	8,390
Finished goods	7,930	7,285
Inventory, Total	$ 19,605	$ 16,000

Share Based Compensation - Summ

Share Based Compensation - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Stockholders Equity Note [Abstract]
Number of Shares Outstanding, Beginning Balance | shares	13,861,000
Number of Shares Granted | shares	3,075,000
Number of Shares Exercised | shares	195,000
Number of Shares Cancelled/Forfeited | shares	243,000
Number of Shares Outstanding, Ending Balance | shares	16,498,000
Number of Shares Exercisable, Ending Balance | shares	11,462,000
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 2.41
Weighted Average Exercise Price Granted | $ / shares	2.73
Weighted Average Exercise Price Exercised | $ / shares	1.99
Weighted Average Exercise Price Cancelled/Forfeited | $ / shares	2.89
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	2.47
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 2.31
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	6 years 9 months 18 days
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	5 years 8 months 12 days
Aggregate Intrinsic Value Outstanding, Ending Balance | $	$ 6,089
Aggregate Intrinsic Value Exercisable, Ending Balance | $	$ 5,997

Share Based Compensation - Su_2

Share Based Compensation - Summary of PSU and RSU Award Activity Under Plan (Detail)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	1,841,000
Number of Shares, Granted	605,000
Number of Shares, Incremental shares earned	77,000
Number of Shares, Vested/settled	(388,000)
Number of Shares, Forfeited/expired	(395,000)
Number of Shares, Ending Balance	1,740,000
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 3
Weighted Average Grant Date Fair Value, Granted | $ / shares	2
Weighted Average Grant Date Fair Value, Vested/settled | $ / shares	3.11
Weighted Average Grant Date Fair Value, Forfeited/expired | $ / shares	3.12
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 2.61
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	1,401,000
Number of Shares, Granted	1,078,000
Number of Shares, Vested/settled	(772,000)
Number of Shares, Forfeited/expired	(45,000)
Number of Shares, Ending Balance	1,662,000
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 2.82
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.73
Weighted Average Grant Date Fair Value, Vested/settled | $ / shares	2.79
Weighted Average Grant Date Fair Value, Forfeited/expired | $ / shares	2.92
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 2.77

Share Based Compensation - Addi

Share Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares withheld to meet employees' statutory income tax obligation	419,000	362,000
Amounts paid to taxing authorities for employees’ tax obligations	$ 1,350	$ 1,063
Employees Tax Obligations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts paid to taxing authorities for employees’ tax obligations	$ 1,350	$ 1,063
Performance Stock Units [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Stock Units [Member] | Long Term Incentive Program [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award percentage	0.00%
Performance Stock Units [Member] | Long Term Incentive Program [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award percentage	150.00%

Share Based Compensation - Su_3

Share Based Compensation - Summary of Share Based Compensation Allocation Expense (Detail) - Long Term Incentive Program [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 1,987	$ 1,634	$ 3,965	$ 3,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	875	758	1,756	1,666
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	525	371	1,082	702
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 587	$ 505	$ 1,127	$ 632

Revenues, Significant Custome_3

Revenues, Significant Customers and Concentrations of Risk - Summary of Revenue Disaggregated by Types of Goods and Services and Major Product (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Total revenue	$ 32,384	$ 28,433	$ 65,463	$ 51,719
Total Product Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	24,665	20,620	51,762	38,920
Total Product Revenue [Member] | Proprietary Product [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	14,846	8,984	27,412	13,755
Total Product Revenue [Member] | Partnered Product [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	9,819	11,636	24,350	25,165
Licensing and Development Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2,687	2,239	4,442	3,154
Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 5,032	$ 5,574	$ 9,259	$ 9,645

Revenues, Significant Custome_4

Revenues, Significant Customers and Concentrations of Risk - Summary of Revenues Disaggregated by Customer Location (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Total revenues	$ 32,384	$ 28,433	$ 65,463	$ 51,719
United States of America [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	31,798	27,542	64,268	48,727
Europe [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	$ 586	788	$ 1,195	2,878
Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenues		$ 103		$ 114

Revenues, Significant Custome_5

Revenues, Significant Customers and Concentrations of Risk - Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue (Detail) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Teva [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	40.00%	42.00%	41.00%	44.00%
AMAG [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	8.00%	19.00%	12.00%	19.00%
AmerisourceBergen Corporation [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	13.00%	11.00%	13.00%
AmerisourceBergen Corporation [Member] | Maximum [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage				10.00%
McKesson Corporation [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	11.00%		11.00%
McKesson Corporation [Member] | Maximum [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage		10.00%		10.00%
Cardinal Health [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	13.00%		11.00%
Cardinal Health [Member] | Maximum [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage		10.00%		10.00%

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Dilutive effect of stock options and other equity-based awards	3,525,000
Potentially dilutive stock options and other share-based awards excluded from dilutive loss per share		19,900,000	19,264,000